Related Experiment Videos
[Verteporfin and photosensitivity in diabetic]
V M Asensio Sánchez1, A Corral Azor, A García Pascual
1Hospital General, Medina del Campo, Valladolid, España.
Archivos De La Sociedad Espanola De Oftalmologia
|June 6, 2003
Summary
Photodynamic therapy (PDT) with verteporfin can cause severe skin photosensitivity reactions. Physicians should monitor patients for adverse effects, especially those with diabetes using sulfonylureas.
Area of Science:
- Ophthalmology
- Dermatology
Background:
- Myopic neovascular lesions require treatment, with photodynamic therapy (PDT) using verteporfin being a common option.
- Borderline diabetes mellitus may necessitate pharmacological intervention, such as sulfonylureas.
Observation:
- A patient with a myopic neovascular lesion received two PDT treatments with verteporfin.
- Following the second uneventful PDT session, the patient experienced a severe skin photosensitivity reaction approximately 10 hours later.
Findings:
- Verteporfin-based PDT can lead to significant photosensitivity.
- The interaction between verteporfin and sulfonylurea medication in a diabetic patient may exacerbate photosensitivity.
Implications:
- Healthcare providers must be vigilant regarding potential adverse skin reactions to verteporfin.
- Awareness of drug interactions, particularly with diabetes medications, is crucial for managing PDT side effects.